International Breast Cancer Summit

Leading Medicals discussing recent discoveries & advances for the treatment of breast cancer.

[Alfredo Addeo MD @Alfdoc2]

Atezolizumab plus chemotherapy for Asian vs. non-Asian patients with extensive-stage small-cell lung cancer: A propensity score matched pooled analysis of four phase 3 trials - Lung Cancer https://t.co/X1Iwm8U7Q7

[International Lung Cancer Summit @LungSummit]

Will patients on FLAURA2 be on chemo forever? Not at all, says @tnewsomdavis.

At ILCS 2025, he clarified that in FLAURA2, platinum was given for just ~3 months and pemetrexed for around 8. When progression occurs, many patients can even be re-challenged with platinum.

Watch his full talk ⬇️
https://t.co/qBfsppMWQK

[International Lung Cancer Summit @LungSummit]

HER2-targeted TKIs continue to evolve.
At ILCS 2025, @stephanieplsaw compared early-phase data on zongertinib and sevabertinib, both showing high activity in heavily pre-treated HER2-mutant NSCLC. Watch her full talk now: https://t.co/qBfsppMWQK

New results from BEAMION LUNG 1 and SOHO-01 will further define this space at the upcoming ESMO 2025. Don’t miss these data releases – add these key abstracts to your calendar 👇
https://t.co/50RRVPuS18

[International Lung Cancer Summit @LungSummit]

Post-progression after frontline EGFR-TKIs remains a challenge.
At ILCS 2025, @TommyJohn00 outlined current options and ongoing studies, including the COMPEL trial. Watch his full talk now: https://t.co/qBfsppMWQK

Looking ahead, the OptiTROP trial will offer new insights at ESMO 2025. Don’t miss it – add this and other must-see abstracts to your calendar 👇
https://t.co/50RRVPuS18

[International Lung Cancer Summit @LungSummit]

Explore the important emergence of DLL3-targeted T-cell engagers in #SCLC with @g_mountzios at our upcoming roundtable! He'll be joined by @peters_solange and @sands_jacob to discuss much more on small cell lung cancer #SCLC.

⏰ 17th June 2025 at 5PM CEST

Tune in for free ⬇️

[OncoViews @OncoViews]

We’re thrilled to launch OncoNews – your go-to source for the latest in oncology! Expect articles on new drug approvals, groundbreaking research, and more. 📰✨

First up, we’re shining the spotlight on @Prof_Nadia_H and her visionary plans for @myESMO presidency ⬇️

[OncoViews @OncoViews]

Congratulations to @Prof_Nadia_H on her candidacy for @myESMO Presidency! 🎉 We're honored to have her as part of the OncoViews faculty.

Best of luck, Nadia – we know you'll continue to inspire and lead with excellence.

[OncoViews @OncoViews]

🚨 TONIGHT

Be sure to tune in to our upcoming roundtable with global experts, @AOmlin, @dmukherji and @AlisonBirtle!

Explore the latest insights on treatment advances for #mHSCPC, #mCRPC and #mUC.

Join us live at 5PM CET ⬇️

[OncoViews @OncoViews]

Don't miss our next roundtable on the latest advances in prostate and urothelial cancer, hosted by @AOmlin alongside @dmukherji and @AlisonBirtle 👩‍⚕️🧑‍⚕️

Check out the agenda below!

Tune in for free on Wednesday 27th March at 5PM CET ⬇️

[OncoViews @OncoViews]

Discover the latest advances in thoracic surgery in #lungcancer treatment with @BrendonStilesMD, alongside a global panel of experts in oncology, at our next roundtable.

⏰ 24th Jan at 5PM CET

Join the discussion for free ⬇️

[OncoViews @OncoViews]

#ADCs have re-shaped the #BreastCancer treatment landscape in recent years.

Explore the latest developments in this promising therapy approach with @PTarantinoMD in our upcoming roundtable.

⏰ 1st Nov at 5PM CET

Register for free - it's CME-certified ⬇️

[International Lung Cancer Summit @LungSummit]

The #LungSummit23 is a conference for you.

Connect with industry experts, like-minded professionals, and potential collaborators here in Lausanne 🧑‍⚕️👩‍⚕️

Let's advance #LungCancer care through collaborative insights ⬇The #LungSummit23 is a conference for you.

Connect with industry experts, like-minded professionals, and potential collaborators here in Lausanne 🧑‍⚕️👩‍⚕️

Let's advance #LungCancer care through collaborative insights ⬇The #LungSummit23 is a conference for you.

Connect with industry experts, like-minded professionals, and potential collaborators here in Lausanne 🧑‍⚕️👩‍⚕️

Let's advance #LungCancer care through collaborative insights ⬇️

[OncoViews @OncoViews]

What do we know about the current state of biomarkers in #ProstateCancer?

Explore this topic and much more in our roundtable discussion with @AOmlin, @Ecastromarcos and @dmukherji for free ⬇️

[International Lung Cancer Summit @LungSummit]

We're delighted to have Dr. Paul Hofman from @Univ_CotedAzur as a keynote speaker at the upcoming #ILCS23!

Connect with Dr. Hofman to learn more about the latest insights on #LungCancer diagnostics on November 10th ⬇️

[OncoViews @OncoViews]

#ADCs are evolving in the field of genitourinary cancer.

Connect with @shilpaonc in our upcoming roundtable to explore the latest advances in this class of drug for the treatment of #GU cancer.

⏰ 1st Nov at 5PM CET

Sign up below for free ⬇️

[OncoViews @OncoViews]

#ADCs represent an exciting area of ongoing development for the treatment of those with #LungCancer.

Be sure to join @Alfdoc2 in our upcoming roundtable to explore more on this very topic.

⏰ 1st November at 5PM CET

Register your spot below ⬇️

[OncoViews @OncoViews]

Get involved in our upcoming roundtable on #ADCs!

Share your anonymous patient case if you'd like some advice from global experts: @Alfdoc2, @shilpaonc, and @PTarantinoMD 🧑‍⚕️👩‍⚕️

Submit your case below before the 1st November ⬇️

[OncoViews @OncoViews]

💊 Drug approval news:

@Swissmedic_ has approved darolutamide in combination with docetaxel and androgen deprivation therapy for the treatment of adults with metastatic hormone-sensitive #ProstateCancer.

Read more on https://t.co/i5s3SaFDOj ⬇️

[OncoViews @OncoViews]

Check out the new @IASLC atlas of molecular testing in #LungCancer 🫁

Created by pathologists and oncologists, the book covers all current and emerging targets from both a diagnostic and clinical point of view.

Get your copy below ⬇️
https://t.co/AByYMlugS8

[OncoViews @OncoViews]

New @myESMO guidelines provides key recommendations for using prognostic estimates in those with advanced #cancer in the last months of life.

Check out the #OpenAccess article in @ESMO_Open ➡️ https://t.co/1QYTa0IInB